Profile picture

Professor Ulrich Laufs

University Hospital Leipzig, Leipzig (Germany)
Follow
Biography
Ulrich Laufs is Chair and Professor of Cardiology at Leipzig University, Germany. After completing his training at the University of Hamburg, he served a residency at the University of Cologne and spent 2 years as post-doctoral researcher at the Brigham and Women’s Hospital in Boston, USA. Before moving to Leipzig in 2017, he was Vice-chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland in Homburg, Germany. Professor Laufs has published multiple experimental and clinical studies in the areas of ‘heart failure’, ‘heart and brain’ and ‘prevention’ with special interest in lipoprotein metabolism. He has received numerous honours, serves in several editorial boards of international cardiovascular journals and holds positions in cardiovascular societies.
Logo ESC

Contributor content

Dyslipidaemia: novel diagnostics and therapy options
Session
Dyslipidaemia: novel diagnostics and therapy options
30 August 2024
Statin therapy: clinical role and current challenges
Session
Statin therapy: clinical role and current challenges
26 August 2022
Great Debate: controversy – do patients benefit from omega-3 fatty acids?
Session
Great Debate: controversy – do patients benefit from omega-3 fatty acids?
27 August 2021
Congress committee e-posters choice in  preventive cardiology and special populations
Session
Congress committee e-posters choice in preventive cardiology and special populations
27 August 2021
Lipid modification for the 21st century
Session
Lipid modification for the 21st century
3 September 2019
Evolving concepts in lipidology
Session
Evolving concepts in lipidology
3 September 2019
How good/bad are we in treating lipids
Session
How good/bad are we in treating lipids
1 September 2019
Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
Session
Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
27 August 2018
Meet the trialist - ARRIVE - Aspirin to Reduce Risk of Initial Vascular Events
Session
Meet the trialist - ARRIVE - Aspirin to Reduce Risk of Initial Vascular Events
27 August 2018
Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
Session
Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
26 August 2018

ESC 365 is supported by